FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026099053> ?p ?o ?g. }

• W3026099053 endingPage "S91" @default.
• W3026099053 startingPage "S90" @default.
• W3026099053 abstract "To compare economic and clinical outcomes in patients treated with current formulation of Surgiflo® or Floseal during cardiovascular surgeries. A retrospective analysis was conducted using Premier Hospital Database (2012-2018Q2). Eligible patients were required to have a cardiovascular surgery during an inpatient visit between 1/1/2013-06/1/2018, were ≥18 years old at the time of admission, and had received current formulation of Surgiflo® or Floseal during surgery. Patients in the two treatment groups were matched using their calculated propensity scores (1:3 variable ratio), surgery year, and type of surgery (i.e., aortic, coronary artery bypass grafting, valve, other). Outcomes included bleeding events, blood transfusion, length of stay (LOS), intensive care unit (ICU) admission, total costs, surgery duration, and readmission within 30-60-90 days. Outcomes were assessed using descriptive analysis and compared between Surgiflo® and Floseal groups using generalized estimating equations. The final study sample included 5,768 patients for each treatment group (mean age=66.5 years [SD=11.2]; 66% males). In both Floseal, and Surgiflo® groups, approximately 31% of patients required blood transfusions within 0-1 days [odds ratio (OR): 1.04; 95% confidence interval (CI): 0.97-1.11)] and 7% within 2-4 days (OR: 1.02; 95%CI: 0.90-1.16) of surgery. Compared to Floseal, Surgiflo® patients had 11% higher ICU admissions (OR: 1.68; 95%CI: 1.56-1.80), longer surgery duration (306 vs. 299 minutes, P<0.05), an average of $2,682 lower hospitalization cost ($44,146 vs. $46,828 P<0.05), and a significantly lower risk of readmission at 30-60-90 days post-discharge (27%, 13% and 12% less likely respectively; all p<0.05). Other outcomes including bleeding, mortality and LOS were comparable (P>0.05). This study included a large sample of patients undergoing cardiovascular surgery over the past 7 years. The results focus on newer hemostatic matrix formulations and suggest relatively comparable clinical outcomes across products. Additionally, these results suggest lower overall hospitalization costs for Surgiflo® compared to Floseal." @default.
• W3026099053 created "2020-05-29" @default.
• W3026099053 creator A5061587092 @default.
• W3026099053 creator A5064798809 @default.
• W3026099053 creator A5067868620 @default.
• W3026099053 creator A5072787727 @default.
• W3026099053 creator A5088771081 @default.
• W3026099053 date "2020-05-01" @default.
• W3026099053 modified "2023-09-30" @default.
• W3026099053 title "PCV8 REAL-WORLD ECONOMIC AND CLINICAL OUTCOMES ASSOCIATED WITH CURRENT HEMOSTATIC MATRIX USE IN CARDIOVASCULAR SURGERY" @default.
• W3026099053 doi "https://doi.org/10.1016/j.jval.2020.04.113" @default.
• W3026099053 hasPublicationYear "2020" @default.
• W3026099053 type Work @default.
• W3026099053 sameAs 3026099053 @default.
• W3026099053 citedByCount "0" @default.
• W3026099053 crossrefType "journal-article" @default.
• W3026099053 hasAuthorship W3026099053A5061587092 @default.
• W3026099053 hasAuthorship W3026099053A5064798809 @default.
• W3026099053 hasAuthorship W3026099053A5067868620 @default.
• W3026099053 hasAuthorship W3026099053A5072787727 @default.
• W3026099053 hasAuthorship W3026099053A5088771081 @default.
• W3026099053 hasBestOaLocation W30260990531 @default.
• W3026099053 hasConcept C126322002 @default.
• W3026099053 hasConcept C141071460 @default.
• W3026099053 hasConcept C156957248 @default.
• W3026099053 hasConcept C167135981 @default.
• W3026099053 hasConcept C2776376669 @default.
• W3026099053 hasConcept C2778789114 @default.
• W3026099053 hasConcept C2780014101 @default.
• W3026099053 hasConcept C44249647 @default.
• W3026099053 hasConcept C71924100 @default.
• W3026099053 hasConceptScore W3026099053C126322002 @default.
• W3026099053 hasConceptScore W3026099053C141071460 @default.
• W3026099053 hasConceptScore W3026099053C156957248 @default.
• W3026099053 hasConceptScore W3026099053C167135981 @default.
• W3026099053 hasConceptScore W3026099053C2776376669 @default.
• W3026099053 hasConceptScore W3026099053C2778789114 @default.
• W3026099053 hasConceptScore W3026099053C2780014101 @default.
• W3026099053 hasConceptScore W3026099053C44249647 @default.
• W3026099053 hasConceptScore W3026099053C71924100 @default.
• W3026099053 hasLocation W30260990531 @default.
• W3026099053 hasOpenAccess W3026099053 @default.
• W3026099053 hasPrimaryLocation W30260990531 @default.
• W3026099053 hasRelatedWork W128001744 @default.
• W3026099053 hasRelatedWork W2010414248 @default.
• W3026099053 hasRelatedWork W2076929529 @default.
• W3026099053 hasRelatedWork W2588964980 @default.
• W3026099053 hasRelatedWork W2931659891 @default.
• W3026099053 hasRelatedWork W2953854568 @default.
• W3026099053 hasRelatedWork W3022091582 @default.
• W3026099053 hasRelatedWork W4296374087 @default.
• W3026099053 hasRelatedWork W4318245710 @default.
• W3026099053 hasRelatedWork W96175412 @default.
• W3026099053 hasVolume "23" @default.
• W3026099053 isParatext "false" @default.
• W3026099053 isRetracted "false" @default.
• W3026099053 magId "3026099053" @default.
• W3026099053 workType "article" @default.